The availability of regulatory sequences directing tissue-specific expression of transgenes in genetically modified mice and large animals is a prerequisite for the development of adequate models for human diseases. The rat insulin 2 gene (Ins2) promoter, widely used to achieve transgene expression in pancreatic -cells of mice, also directs expression to extrapancreatic tissues and performs poorly in isolated pancreatic islets of human, mouse, and pig. To evaluate whether the full 5' untranslated region (UTR) of the porcine insulin gene (INS) confers robust and specific expression in -cells we generated an expression cassette containing 1500 bp of the porcine INS 5' UTR and the 3' UTR of the bovine growth hormone gene (GH). The cassette was designed to allow easy exchange of the sequences to be expressed and easy removal of the vector backbone from the expression cassette. To evaluate the properties of the cassette, we initially cloned a cDNA encoding human betacellulin, a growth factor known to affect structural and functional parameters of -cells. After confirming the functionality and specificity of the construct in vitro, transgenic mouse lines were generated by pronuclear DNA microinjection. Using RT-PCR, immunohistochemistry and immunofluorescence, we show that transgenic mice expressed human betacellulin exclusively in -cells. Confirming the proposed insulinotropic effect of betacellulin, transgenic mice showed improved glucose tolerance. We conclude that the newly designed expression cassette containing 1.500 bp of the porcine insulin promoter 5' UTR confers robust and specific transgene expression to -cells in vitro and in transgenic mice.
INTRODUCTION
Genetically modified mice greatly contributed to advance our understanding of the physiology and pathology of the endocrine pancreas. A key component of this technology is the targeted expression of gene products in specific cell types of the pancreatic islets.
The rat (Dahl et al. 1996; Hanahan 1985; Vasavada et al. 1996) , mouse (Hara et al. 2003) , and human (Hotta et al. 1998; Krakowski et al. 1999) insulin promoters have been frequently used to direct expression of oncogenes, hormones, growth factors, transcription factors, reporter genes, and more recently of the enzyme Cre recombinase (Ahlgren et al. 1998; Dor et al. 2004; Gannon et al. 2000; Postic et al. 1999 ) specifically to pancreatic -cells in transgenic mice. A major caveat of the rat insulin promoter, however, is the reported ectopic expression in certain areas of the brain, potentially resulting in phenotypes in both -cells and neural cells (Gannon et al. 2000; Martin et al. 2003) .
While the mouse model is appropriate for answering basic questions of -cell pathophysiology, translational studies, particularly regarding islet transplantation, would greatly benefit from large animal models. Pigs seem to be the best candidates for this purpose: they are readily available, produce a large progeny, and regulate blood glucose levels similarly to humans. In addition, porcine neonatal islet cell clusters (Cardona et al. 2006; MacKenzie et al. 2003) and islets from adult pigs (Hering et al. 2006 ) are an interesting source of insulin-producing tissue for transplantation purposes. In this regard, there is an urgent need of genetic tools for the tissue-specific delivery of gene products to porcine pancreatic -cells. Unfortunately, the rat insulin promoter was shown to perform very poorly in isolated islets from pigs, human, and mice (Londrigan et al. 2007 ). The porcine insulin gene (INS) contains three exons and two introns, and highly conserved cis-acting elements were identified in the 5' flanking region (Han & Tuch 2001) . Recently, a fragment of the porcine INS promoter containing approximately 680 bp of the 5' untranslated region (UTR) was active in a cell type-specific manner in vitro, but failed to confer expression in transgenic mice (Watanabe et al. 2007 ). Addition of a cytomegalovirus enhancer resulted in transgene expression both in vivo and in vitro, but at the expense of cell type specificity (Watanabe et al. 2007 ). Here, we report that an expression cassette containing 1500 bp of the 5' UTR from the porcine INS gene (including the first exon and the first intron) and the 3' UTR of the bovine growth hormone gene (GH) is efficient to drive transgene expression in a robust and specific manner to -cells in vitro and in transgenic mouse models. To test the functionality of the cassette we Page 4 of 17 A c c e p t e d M a n u s c r i p t 4 4 have chosen the cDNA encoding human betacellulin, a ligand of the EGFR ) known to stimulate -cell differentiation in vitro and to improve glucose tolerance in diabetic models and in transgenic mice.
MATERIALS AND METHODS

Construction of the transgene
A ~1500-bp fragment of the 5' flanking region of the porcine insulin gene (INS) was amplified by polymerase chain reaction (Expand High Fidelity PLUS PCR System, Roche Diagnostics, Mannheim, Germany) using the sense primer (SalI restriction site underlined) 5'-TGT ACT GTC GAC GAG TTC AGC TGA GCT GGC TC-3' and the antisense primer (HindIII restriction site underlined) 5'-CGC TAG AAG CTT TGG GGG ACG GGC GGC GTT-3' (see Figure 1A ). Template was a plasmid pGEM+INS (Flaswinkel et al., unpulished) 
Cell transfection
All cell culture reagents were purchased from PAA (Pasching, Austria). Immortalized mouse hepatocytes (a gift from Dr. D. Accili, Columbia University, NY), human embryonal kidney 293 cells (HEK 293) , and the MIN-6 mouse pancreatic -cell line (a gift from Dr. J.
Miyazaki, Osaka University) were cultured in low glucose (1 g/L) DMEM medium with M a n u s c r i p t 5 10% fetal bovine serum. 2x10 6 cells were transfected either with the PIP-hBTC construct or with the pGMAX-GFP vector using the Amaxa Nucleofector system (Lonza, Cologne, Germany). After transfection cells were cultured in high glucose medium (4.5 g/L) for 48 hours and harvested for protein isolation.
Western blot analyses
Cells were homogenized in lysis buffer (Cell Signaling, Danvers, MA, USA) and 30 µg total protein were separated by SDS-PAGE and transferred to PVDF membranes by electroblotting. Loading of equal amounts of protein for each sample was verified with Ponceau staining. A rabbit antibody that reacts specifically with human BTC (R&D, Systems, Wiesbaden, Germany) and a secondary HRP-conjugated goat anti-rabbitantibody (Cell Signaling) were employed. Bound antibodies were detected using an enhanced chemiluminescence detection reagent (ECL Advance Western Blotting detection kit, GE Healthcare) and appropriate x-ray films (GE Healthcare).
Generation of transgenic mice
The PIP-hBTC expression cassette was released from the vector backbone by SalI/NotI double digestion, purified by agarose gel electrophoresis, diluted to 2 ng/µl in injection buffer (Nagy et al. 2003) and employed for pronuclear microinjection into fertilized oocytes from the inbred strain FVB/N. The injected zygotes were transplanted into the oviducts of pseudopregnant females and potential founder animals were screened by PCR. The animals had free access to a standard rodent diet (V1534, Ssniff, Soest, Germany) and water. All experiments were approved by the author's institutional committee on animal care and carried out in accordance with the German Animal Protection Law with permission from the responsible veterinary authority.
Immunohistochemistry and immunofluorescence
Animals were anesthetized and killed by cervical dislocation. Pancreata and other organs were removed immediately after the animal's death, carefully trimmed free of adjacent tissues, weighed, fixed in 4% paraformaldehyde (in PBS, pH 7.4) and embedded in paraffin. For immunohistochemical localization of BTC, the streptavidin-biotin method was applied. Five µm thick sections were cut, deparaffinized and heated for 20 min in a microwave in 10 mM sodium citrate buffer for antigen retrieval. The primary antibody (same as for Western blot, dilution 1:300) was incubated for 2 hours at room temperature, followed by a biotin-conjugated rabbit anti-goat secondary antibody (Dako, Hamburg, A c c e p t e d M a n u s c r i p t 6 6 Germany). Diaminobenzidine (Sigma, Taufkirchen, Germany) served as chromogen.
Finally, the sections were counterstained with hematoxylin. Colocalization of BTC with insulin and glucagon was studied by multicolor immunofluorescence: Five µm paraffin sections pretreated as described above were incubated for 1 hour at room temperature with the primary antibodies diluted in Tris-buffered saline (TBS, pH 7.6). After three washes with TBS, sections were incubated for 1 hour with fluorescence-labeled secondary antibodies. We used the previously described goat anti-human BTC antibody (R&D, Systems, Wiesbaden, Germany), rabbit anti-glucagon and guinea pig anti-insulin antibodies (Dako, Hamburg, Germany 
Reverse transcriptase PCR
Isolation of total RNA, first strand cDNA synthesis, and semiquantitative RT-PCR were performed as described earlier (Schneider et al. 2001 ). The primers previously described for amplifying the human BTC cDNA were employed for the detection of transgenespecific BTC mRNA expression. The integrity of the template cDNA was confirmed by amplifying a sequence of the -actin gene (sense, 5'-GGCATCGTGATGGACTCC-3';
antisense, 5'-GTCGGAAGGTGGACAGGG-3').
Glucose metabolism studies
After fasting for 14 hours, blood was drawn from the retro-orbital sinus of ether anesthetized mice for determination of blood glucose. For glucose tolerance test, fasted mice (16 hours) were injected intraperitoneally with glucose (1.5 g/kg body weight). Blood samples were obtained by puncture of the tail vein immediately before glucose A c c e p t e d M a n u s c r i p t 7 7 administration and at the indicated time points after injection. A glucometer (Precision, Abbott Diabetes Care, Wiesbaden, Germany) was used to determine glucose levels.
Statistical analysis
The results of glucose tolerance tests were statistically evaluated by analysis of variance 
RESULTS
Evaluation of promoter activity in vitro
To evaluate the overall functionality and specificity of the construct, cell lines representing different cell types were transfected either with the PIP-hBTC or with the pMAX-GFP vector. Transfection efficiency, evaluated 24 hours after the transfection by monitoring
GFP fluorescence, was similar for all lines (~50% green cells, data not shown). After 48
hours, cells transfected with PIP-hBTC were harvested for protein isolation and subjected to Western blot analysis employing an antibody that recognizes specifically human BTC.
As shown in Figure 1C , human BTC was clearly detected in protein extracts from mouse MIN-6 -cells, but not in extracts from mouse hepatocytes or human embryonic kidney (HEK 293) cells. These in vitro findings indicate that the PIP-hBTC construct is functional and suggest that the employed porcine insulin promoter is selectively activated in -cells.
Generation of PIP-hBTC transgenic mice
After microinjection of the PIP-hBTC construct, forty mice were born and three of them were identified as being transgenic by PCR and Southern blot analyses (data not shown).
One transgenic animal (#11) consistently failed to generate transgenic progeny and was therefore sacrificed. The remaining two founders (#16 and #38) transmitted the transgene to their descendents in a mendelian fashion, originating two PIP-hBTC transgenic lines (L2 and L3, respectively).
Specific expression of the PIP-hBTC transgene in insulin-positive cells of the endocrine pancreas
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To evaluate expression of the construct in different organs, RT-PCR analysis was performed for RNA samples from lung, liver, small intestine, kidney, muscle, and pancreatic islets. As shown in Figure 2A , transgene expression was detected exclusively in the pancreatic islets of L2 transgenic mice. The same result was obtained for L3 mice (data not shown). Immunohistochemistry against hBTC also failed to detect positive cells in the above mentioned and additional organs such as the heart, stomach and brain (data not shown). To evaluate whether the used porcine insulin promoter directs expression to certain regions of the ventral brain, as described for the rat insulin promoter (Gannon et al. 2000) , we additionally studied the pons, caudate putamen, and the hypothalamus. In none of these brain regions we detected transgene transcripts by RT-PCR ( Figure 2B ) or hBTC by immunohistochemistry (data not shown). In the pancreas of L2 and L3 transgenic mice, hBTC-positive cells were readily detected within the islets, but not in the exocrine compartment ( Figure 2C ). The number of cells expressing the transgene was considerably higher in the islets of L3 transgenic mice as compared to founder #11 and L2 animals ( Figure 2D ). To further evaluate whether the employed PIP sequence specifically directs expression of the transgene to insulin-producing cells, we examined colocalization of hBTC with insulin and glucagon by multicolor immunofluorescence and confocal laser scanning microscopy. In both transgenic PIP-hBTC and non-transgenic control mice, insulin-specific immunofluorescence was evident in the cytoplasm of the majority of islets cells, while a smaller proportion of the cells was negative for insulin and positive for glucagon ( Figure 2E) . Importantly, in transgenic animals, hBTC staining was only observed in insulin-positive cells, indicating that the PIP sequence employed is adequate for targeting exclusively pancreatic -cells ( Figure 2E) . Evaluation of pancreatic islets from transgenic fetuses sacrificed on day 17.5 of pregnancy revealed that the -cell specificity of the employed promoter is already present at this early stage of islet formation ( Figure 2F ).
PIP-hBTC transgenic mice show no overt phenotypic abnormalities
Transgenic mice from both lines developed normally, were fertile, and did not show any obvious abnormalities. Histological analysis of the pancreas did not reveal any pathological alteration in PIP-hBTC transgenic mice, in agreement with our previous results in mice with overexpression of BTC in both the endocrine and the endocrine compartment (Dahlhoff et al. 2009 ). Body and organ weights were evaluated in transgenic males and females and gender-matched littermates at the age of 5 months A c c e p t e d M a n u s c r i p t 9 9 (n=4-6/group). No differences were observed in total body weight, and in absolute or relative organ weights, irrespective of the line (data not shown).
PIP-hBTC transgenic mice show improved glucose tolerance
Intraperitoneal glucose tolerance tests showed that the blood glucose concentrations rose similarly in control and in PIP-hBTC transgenic mice from line 2 and 3 after glucose injection ( Figure 3A) . However, glucose clearance was improved in transgenic mice from both lines in the second half of the test period ( Figure 3A) . When the results were expressed as area under the glucose curve, a significant difference was observed between L2 and L3 transgenic mice and their control littermates, respectively ( Figure   3B ).
DISCUSSION
Here we show that an expression cassette containing 1500 bp of the 5' UTR from the porcine insulin gene (including the first exon and the first intron) and the 3' UTR of the bovine GH gene is efficient for driving transgene expression in a robust and specific manner to -cells in vitro and in transgenic mice.
To test the functionality of the cassette we have chosen a cDNA encoding the EGFR ligand betacellulin . Betacellulin is known to stimulate -cell differentiation in vitro and to improve glucose tolerance in diabetic models and in transgenic mice (reviewed in (Dahlhoff et al. 2009 ) -although a few studies failed to demonstrate such an effect (Sjoholm & Kindmark 1999) . Recently, we demonstrated an improved glucose tolerance in mice with ubiquitous overexpression of betacellulin (Dahlhoff et al. 2009; Schneider et al. 2005) . This finding needed cautious interpretation, since betacellulin levels were also higher in other tissues. In the present study we demonstrate an improved glucose tolerance in an animal model with -cell-specific overexpression of betacellulin. Also in agreement with our previous results is the lack of pathological alterations in PIP-hBTC transgenic mice. This is in contrast to the multiple pathological effects including islet disaggregation, fibrosis, and even ductal metaplasia observed in transgenic mice with -cell-specific overexpression of the EGFR ligands EGF (Krakowski et al. 1999 ) and heparin-binding EGF (Means et al. 2003) . This observation indicates that BTC has unique actions on pancreatic islets as compared to other EGFR ligands. The transgenic mouse lines described here are valuable for detailed studies of
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The new expression cassette described here represents a significant improvement over available expression systems in different ways. First, our cassette potentially allows -cell-specific expression of gene products in transgenic mice without the unwanted expression in other tissues such as the central nervous system. Nevertheless, the level and specificity of transgene expression in new lines are always difficult to predict due to position effects and require careful characterization (Martin & Whitelaw 1996) . Second, the ease of exchanging the sequences to be expressed in the cassette and the availability of restriction sites for "rare cutter" enzymes for removing the relevant sequences from the vector backbone render this construct a handy tool for the generation of transgenic mice for -cell specific overexpression of a variety of proteins. Third, it is plausible to predict that the transgene cassette will also perform well in pigs, promoting a widespread use of this species in diabetes research.
M a n u s c r i p t 11 11 M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t Scale bars represent 500 µm in C and 50 µm in D. E,F: Simultaneous visualization of insulin, glucagon, and hBTC by multicolor immunofluorescence and confocal laser scanning microscopy in the islets of an adult PIP-hBTC (E), an adult non-transgenic control mouse (insert in E), and a PIP-hBTC fetus at day 17.5 of pregnancy (F). 
